Journals / Viral Hepatitis Journal / 2016 / Cilt: 22 - Sayı: 3

Pakistan Toplumunda Hepatit C ile İlgili Bir Gözden Geçirme

A Review of Hepatitis C in the General Population in Pakistan

Pages
74–81
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, facilitated access to clinical manifestations should be made to identify risk factors, reduce disease burden and to improve the quality of life of hepatitis C carriers

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To perform a systematic review of the recent scientific literature on hepatitis C infection for epidemiology, genotypes, co-infection, risk factors and management regime in Pakistan.
📊
Key Findings & Data:Present integrated, analyzed updated data, a comprehensive effort to evaluate hepatitis C virus (HCV) disease burden in Pakistan, and to inform public health decision makers.
💡
Conclusion & Impact:Furthermore, facilitated access to clinical manifestations should be made to identify risk factors, reduce disease burden and to improve the quality of life of hepatitis C carriers
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

To perform a systematic review of the recent scientific literature on hepatitis C infection for epidemiology, genotypes, co-infection, risk factors and management regime in Pakistan. Present integrated, analyzed updated data, a comprehensive effort to evaluate hepatitis C virus (HCV) disease burden in Pakistan, and to inform public health decision makers. Literature search was performed using PubMed, Google Scholar and Scopus from peerreviewed journals. Criteria for inclusion and exclusion of pooled data with reference to quality and relevance were set prior to metaanalysis. A total of 129 studies were finally included; more than one study on the same region or group of population was included for comparison and statistical authentication. Hepatitis C is endemic in Pakistan with a 40% raise in the incidence of the disease conferring to resent reports. Data of the last five years from different districts of the country show an abrupt elevation in HCV seroprevalence. HCV genotype 3a remains to be the most prevalent in Pakistan (61.3%). However, in recent years, genotype 1a has raised in the Baluchistan province. A significantly high prevalence in transfusion-transmitted diseases is observed. Management of known risk factor can be a significant parameter to control HCV infection. This review encourages further rigorous research efforts to analyze surveillance of HCV in ruler remote areas of Pakistan. Furthermore, facilitated access to clinical manifestations should be made to identify risk factors, reduce disease burden and to improve the quality of life of hepatitis C carriers

Özet

Bu çalışmada Pakistan'da hepatit C enfeksiyonunun epidemiyolojisi, genotipleri, ko-enfeksiyonları, risk faktörleri ve yönetimi konusunda son dönem bilimsel literatürlerin sistematik bir derlemesi yapılmıştır. Pakistan'daki hepatit C virüsü (HCV) hastalık yükünü değerlendirmek ve halk sağlığı uzmanlarını bilgilendirmek için, kapsamlı bir çalışmayla analiz edilen güncellenmiş veriler günümüze entegre edilmiştir. Literatür araştırmaları PubMed, Google Akademik ve Scopus kullanılarak hakemli dergilerden yapılmıştır. Kalite ve uygunluk için referansla toplanan verilerin dahil edilme ve edilmeme kriterleri meta-analiz için önceden belirlenmiştir. Karşılaştırma ve istatistiksel olarak doğrulama için, benzer bölge veya grup üzerinde birden fazla çalışma, sonuçta toplam 129 çalışma dahil edilmiştir. Güncel raporlara göre insidansta %40 artışla hepatit C Pakistan'da endemiktir. Ülkenin farklı kesimlerinden son 5 yıllık veriler, hepatit C seroprevalansında ani bir yükselişi göstermektedir. HCV 3a genotipi Pakistan'da en yaygın genotip olmaya devam etmektedir. Bununla birlikte son yıllarda genotip 1a Balunchistan eyaletinde artış göstermiştir. Transfüzyonla bulaşan hastalıklarda belirgin olarak yüksek bir prevalans gözlenmiştir. Bilinen risk faktörünün yönetimi HCV enfeksiyonunu kontrol etmek için önemli bir parametre olmalıdır. Bu çalışma Pakistan'ın kırsal bölgelerindeki HCV sürveyans analizi için gelecekte yapılacak araştırmaları teşvik edecektir. Ayrıca, risk faktörlerini belirlemek, hastalık yükünü azaltmak ve hepatit C taşıyıcılarının yaşam kalitesini arttırmak için klinik bulguları kolaylaştırmak gerekir

🔖

Cite This Article

RIAZ, S., IQBAL, A. (2016). Pakistan Toplumunda Hepatit C ile İlgili Bir Gözden Geçirme. Viral Hepatitis Journal, Cilt: 22 - Sayı: 3, 74–81. https://ajindex.com/articles/332691

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333-1342
  2. He S, Lin B, Chu V, Hu Z, Hu X, Xiao J, Wang AQ, Schweitzer CJ, Li Q, Imamura M, Hiraga N, Southall N, Ferrer M, Zheng W, Chayama K, Marugan JJ, Liang TJ. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci Transl Med. 2015;7:282-249
  3. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-873
  4. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-362
  5. Zaman AA, Karim R, Khan ST, Khan SA. Frequecny of hbsag and anti-hcv in asymptomatic healthy blood donors at hmc, Peshawar. KJMS. 2014;1:155-158
  6. Hill AM, Roberts T, Amorosa V, Pourmand K, Matthews G, Cooke G, Khan H, Main J, Brown A, Peter JA, Nelson DR. Can HCV Antigen Testing Replace HCV RNA PCR Analysis, for Diagnosis and Monitoring of Treatment for Hepatitis C?. In Hepatology 2015;07030-5774
  7. Zidan A, Scheuerlein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon. 2012;12:e6894
  8. Debing Y, Jochmans D, Neyts J. Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol. 2013;3:217-224
  9. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A. 2012;109:6205-6210
  10. WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization; 2014
  11. Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Felix J, Ferraz ML, Ferreira PR, Frankova S, Garcia-Samaniego J, Gersto